Rituximab therapy for chronic periaortitis
In a recent report, one patient with periaortitis secondary to IgG4-related systemic disease was successfully treated with rituximab, although the response of the retroperitoneal mass was not described. 8 Rituximab is increasingly used in different autoimmune disorders such as rheumatoid arthritis,...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2012-07, Vol.71 (7), p.1262-1264 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1264 |
|---|---|
| container_issue | 7 |
| container_start_page | 1262 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 71 |
| creator | Maritati, Federica Corradi, Domenico Versari, Annibale Casali, Massimiliano Urban, Maria Letizia Buzio, Carlo Vaglio, Augusto |
| description | In a recent report, one patient with periaortitis secondary to IgG4-related systemic disease was successfully treated with rituximab, although the response of the retroperitoneal mass was not described. 8 Rituximab is increasingly used in different autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides. 9 CP is also thought to have an autoimmune background, given its association with autoimmune diseases 6 10 and with the autoimmunity-predisposing HLA-DRB1*03 allele. 11 The efficacy of rituximab also suggests a crucial pathogenetic role for B cells in CP. [...]rituximab may be effective in CP. |
| doi_str_mv | 10.1136/annrheumdis-2011-201166 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1778093205</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4009192901</sourcerecordid><originalsourceid>FETCH-LOGICAL-b419t-f06ca6e83a8e4f28c4d5f04a93cc32c255eb084db1f823a4a62f8beed07471993</originalsourceid><addsrcrecordid>eNqNkF1LwzAUhoMobk7_gg7EG6F68tE0vXTFqTgURMW7kKYJ69zambSw_XszO4eX3iQcznPe5DwInWG4wpjya1VVbmraRVH6iADGPwfne6iPGReh4rCP-gBAI5bypIeOvJ-FEgQWh6hHSCw45riPLl_Kpl2VC5UPm6lxarke2toN9dTVVamHS-NKVbumbEp_jA6smntzsr0H6G18-5rdR5Pnu4fsZhLlDKdNZIFrxY2gShhmidCsiC0wlVKtKdEkjk0OghU5toJQxRQnVuTGFJCwBKcpHaDzLnfp6q_W-EbO6tZV4UmJk0RASgnEgUo6Srvae2esXLqwhltLDHLjSP5xJDd6ZOcoTJ5u89t8YYrd3K-UAFxsAeW1mlunKh0ydhwHyomAwEUdV_rGrHZ95T4lT2gSy6f3TGYjPoLx44ckgScdny9m__7tN89QkTg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1778093205</pqid></control><display><type>article</type><title>Rituximab therapy for chronic periaortitis</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><creator>Maritati, Federica ; Corradi, Domenico ; Versari, Annibale ; Casali, Massimiliano ; Urban, Maria Letizia ; Buzio, Carlo ; Vaglio, Augusto</creator><creatorcontrib>Maritati, Federica ; Corradi, Domenico ; Versari, Annibale ; Casali, Massimiliano ; Urban, Maria Letizia ; Buzio, Carlo ; Vaglio, Augusto</creatorcontrib><description>In a recent report, one patient with periaortitis secondary to IgG4-related systemic disease was successfully treated with rituximab, although the response of the retroperitoneal mass was not described. 8 Rituximab is increasingly used in different autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides. 9 CP is also thought to have an autoimmune background, given its association with autoimmune diseases 6 10 and with the autoimmunity-predisposing HLA-DRB1*03 allele. 11 The efficacy of rituximab also suggests a crucial pathogenetic role for B cells in CP. [...]rituximab may be effective in CP.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2011-201166</identifier><identifier>PMID: 22586161</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>Abdomen ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived - therapeutic use ; Autoimmune diseases ; Back pain ; Biological and medical sciences ; Disease ; Diseases of the osteoarticular system ; Drug Substitution ; Female ; Humans ; Immunologic Factors - therapeutic use ; Immunomodulators ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Remission Induction ; Retroperitoneal Fibrosis - diagnosis ; Retroperitoneal Fibrosis - drug therapy ; Rituximab ; Treatment Outcome</subject><ispartof>Annals of the rheumatic diseases, 2012-07, Vol.71 (7), p.1262-1264</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2015 INIST-CNRS</rights><rights>Copyright: 2012 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b419t-f06ca6e83a8e4f28c4d5f04a93cc32c255eb084db1f823a4a62f8beed07471993</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/71/7/1262.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/71/7/1262.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3196,23571,27924,27925,77600,77631</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26036280$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22586161$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maritati, Federica</creatorcontrib><creatorcontrib>Corradi, Domenico</creatorcontrib><creatorcontrib>Versari, Annibale</creatorcontrib><creatorcontrib>Casali, Massimiliano</creatorcontrib><creatorcontrib>Urban, Maria Letizia</creatorcontrib><creatorcontrib>Buzio, Carlo</creatorcontrib><creatorcontrib>Vaglio, Augusto</creatorcontrib><title>Rituximab therapy for chronic periaortitis</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>In a recent report, one patient with periaortitis secondary to IgG4-related systemic disease was successfully treated with rituximab, although the response of the retroperitoneal mass was not described. 8 Rituximab is increasingly used in different autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides. 9 CP is also thought to have an autoimmune background, given its association with autoimmune diseases 6 10 and with the autoimmunity-predisposing HLA-DRB1*03 allele. 11 The efficacy of rituximab also suggests a crucial pathogenetic role for B cells in CP. [...]rituximab may be effective in CP.</description><subject>Abdomen</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal, Murine-Derived - therapeutic use</subject><subject>Autoimmune diseases</subject><subject>Back pain</subject><subject>Biological and medical sciences</subject><subject>Disease</subject><subject>Diseases of the osteoarticular system</subject><subject>Drug Substitution</subject><subject>Female</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunomodulators</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Remission Induction</subject><subject>Retroperitoneal Fibrosis - diagnosis</subject><subject>Retroperitoneal Fibrosis - drug therapy</subject><subject>Rituximab</subject><subject>Treatment Outcome</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkF1LwzAUhoMobk7_gg7EG6F68tE0vXTFqTgURMW7kKYJ69zambSw_XszO4eX3iQcznPe5DwInWG4wpjya1VVbmraRVH6iADGPwfne6iPGReh4rCP-gBAI5bypIeOvJ-FEgQWh6hHSCw45riPLl_Kpl2VC5UPm6lxarke2toN9dTVVamHS-NKVbumbEp_jA6smntzsr0H6G18-5rdR5Pnu4fsZhLlDKdNZIFrxY2gShhmidCsiC0wlVKtKdEkjk0OghU5toJQxRQnVuTGFJCwBKcpHaDzLnfp6q_W-EbO6tZV4UmJk0RASgnEgUo6Srvae2esXLqwhltLDHLjSP5xJDd6ZOcoTJ5u89t8YYrd3K-UAFxsAeW1mlunKh0ydhwHyomAwEUdV_rGrHZ95T4lT2gSy6f3TGYjPoLx44ckgScdny9m__7tN89QkTg</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>Maritati, Federica</creator><creator>Corradi, Domenico</creator><creator>Versari, Annibale</creator><creator>Casali, Massimiliano</creator><creator>Urban, Maria Letizia</creator><creator>Buzio, Carlo</creator><creator>Vaglio, Augusto</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20120701</creationdate><title>Rituximab therapy for chronic periaortitis</title><author>Maritati, Federica ; Corradi, Domenico ; Versari, Annibale ; Casali, Massimiliano ; Urban, Maria Letizia ; Buzio, Carlo ; Vaglio, Augusto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b419t-f06ca6e83a8e4f28c4d5f04a93cc32c255eb084db1f823a4a62f8beed07471993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Abdomen</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal, Murine-Derived - therapeutic use</topic><topic>Autoimmune diseases</topic><topic>Back pain</topic><topic>Biological and medical sciences</topic><topic>Disease</topic><topic>Diseases of the osteoarticular system</topic><topic>Drug Substitution</topic><topic>Female</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunomodulators</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Remission Induction</topic><topic>Retroperitoneal Fibrosis - diagnosis</topic><topic>Retroperitoneal Fibrosis - drug therapy</topic><topic>Rituximab</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maritati, Federica</creatorcontrib><creatorcontrib>Corradi, Domenico</creatorcontrib><creatorcontrib>Versari, Annibale</creatorcontrib><creatorcontrib>Casali, Massimiliano</creatorcontrib><creatorcontrib>Urban, Maria Letizia</creatorcontrib><creatorcontrib>Buzio, Carlo</creatorcontrib><creatorcontrib>Vaglio, Augusto</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maritati, Federica</au><au>Corradi, Domenico</au><au>Versari, Annibale</au><au>Casali, Massimiliano</au><au>Urban, Maria Letizia</au><au>Buzio, Carlo</au><au>Vaglio, Augusto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rituximab therapy for chronic periaortitis</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>71</volume><issue>7</issue><spage>1262</spage><epage>1264</epage><pages>1262-1264</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>In a recent report, one patient with periaortitis secondary to IgG4-related systemic disease was successfully treated with rituximab, although the response of the retroperitoneal mass was not described. 8 Rituximab is increasingly used in different autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides. 9 CP is also thought to have an autoimmune background, given its association with autoimmune diseases 6 10 and with the autoimmunity-predisposing HLA-DRB1*03 allele. 11 The efficacy of rituximab also suggests a crucial pathogenetic role for B cells in CP. [...]rituximab may be effective in CP.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>22586161</pmid><doi>10.1136/annrheumdis-2011-201166</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2012-07, Vol.71 (7), p.1262-1264 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_proquest_journals_1778093205 |
| source | MEDLINE; BMJ Journals - NESLi2 |
| subjects | Abdomen Aged, 80 and over Antibodies, Monoclonal, Murine-Derived - therapeutic use Autoimmune diseases Back pain Biological and medical sciences Disease Diseases of the osteoarticular system Drug Substitution Female Humans Immunologic Factors - therapeutic use Immunomodulators Male Medical sciences Middle Aged Pharmacology. Drug treatments Remission Induction Retroperitoneal Fibrosis - diagnosis Retroperitoneal Fibrosis - drug therapy Rituximab Treatment Outcome |
| title | Rituximab therapy for chronic periaortitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T05%3A46%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rituximab%20therapy%20for%20chronic%20periaortitis&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Maritati,%20Federica&rft.date=2012-07-01&rft.volume=71&rft.issue=7&rft.spage=1262&rft.epage=1264&rft.pages=1262-1264&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2011-201166&rft_dat=%3Cproquest_cross%3E4009192901%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1778093205&rft_id=info:pmid/22586161&rfr_iscdi=true |